Hims & Hers Health Shares Fall After Q3 Earnings Miss and Lowered 2026 Guidance
Hims & Hers Health (HIMS) saw its stock price decline approximately 2% in after-hours trading following the release of third-quarter financial results. The telehealth company reported misses on both top-line revenue and bottom-line earnings expectations, prompting investor concern regarding growth momentum. In addition to the quarterly miss, management narrowed its long-term outlook by adjusting its 2026 guidance for both revenue and EBITDA. The company now projects full-year 2026 revenue to fall within a range of $3.13 billion to $3.15 billion, signaling a more cautious growth trajectory than previously anticipated.
Tickers: $HIMS
Topics: earnings miss EBITDA guidance revenue guidance telehealth
Read the full article at Seeking Alpha
Part of the story Encompass Health Corp - 10-Q Filing (10 articles)